Lisata Therapeutics, Inc. (LSTA)
NCM · Healthcare · Biotechnology
$3.56
+2.30%
Closing price as of 2026-06-12 · Source: TEK2day Finance
Key Metrics
Market Cap
$32.4M
Shares Outstanding
9.1M
P/S (TTM)
191x
Exchange
NCM
Currency
USD
About Lisata Therapeutics, Inc.
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cancer and glioblastoma multiforme in combination with range of anti-cancer regimens. The company was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 70K | 0.00 | 100K | 0.00 |
| Operating Income | -4.9M | -4.4M | -3.1M | -4.9M |
| Net Income | -4.7M | -4.2M | -3.0M | -4.5M |
| Diluted EPS | $-0.54 | $-0.49 | $nan | $-0.50 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 1.0M | 170K |
| Operating Income | -57.6M | -25.7M | -22.4M | -18.2M |
| Net Income | -54.2M | -20.8M | -20.0M | -16.6M |
| Diluted EPS | $-10.47 | $-2.58 | $-2.40 | $-1.91 |